NCT04388475 2025-08-12Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent GlioblastomaOblato, Inc.Phase 2 Completed57 enrolled
NCT05561374 2024-11-29Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade GliomaOblato, Inc.Phase 1 Active not recruiting16 enrolled
NCT03649464 2022-10-07Investigation of Oral OKN-007 in Recurrent High-grade Glioma ParticipantsOblato, Inc.Phase 1/2 Withdrawn